01801 Overview

Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.

CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.

Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.

Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.

Market Performance: The Hang Seng Index (HSI) fell by 491 points (1.8%) to close at 26,590, with significant declines also seen in the HSTI and HSCEI, which dropped 114 points (2.1%) and 189 points (2.1%) respectively, amid a market turnover of $250.99 billion.

Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, Alibaba, and Xiaomi experienced notable declines, with Meituan down 4.2% and Tencent down 3.3%, reflecting a trend of short selling across these companies.

Constituents on the Move: Several constituents saw significant price changes, including Sino Biopharma and Hansoh Pharma, which dropped 6.6% and 6.4% respectively, while WH Group rose by 4.4%, reaching a new high.

Other Notable Stocks: Stocks such as MIRXES-B and CTG Duty-Free faced substantial losses, with MIRXES-B down 21.7%, while KB Laminates and CNBM saw gains of 12.4% and 10.5%, respectively, also hitting new highs.

Market Performance: The Hang Seng Index (HSI) fell by 523 points (1.9%) to 26,558, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 2.4% and 2.1%, respectively.

Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, and Alibaba saw significant drops, with Meituan down 4.8% and Tencent down 3.4%, amidst high short selling ratios.

Notable Declines in Constituents: Several constituents, including Hansoh Pharma and Sino Biopharma, reported steep declines, with Hansoh Pharma down 6.5% and Sino Biopharma down 6.1%.

Gainers Amidst Losses: Despite the overall market downturn, a few stocks like WH Group and Henderson Land recorded gains, with WH Group up 3.2% and Henderson Land up 1.7%, both hitting new highs.

Market Overview: The Hong Kong bourse opened lower, with the Hang Seng Index (HSI) dropping 509 points or 1.9% to 26,572, amid a turnover of HKD124.419 billion.

Pharmaceutical Sector Decline: Pharmaceutical stocks were the biggest losers, with notable declines in HANSOH PHARMA, SINO BIOPHARM, and CSPC PHARMA, all experiencing significant short selling.

Insurance Sector Struggles: Chinese insurers faced pressure, with major companies like CHINA LIFE and PING AN seeing substantial losses, contributing to a broader decline in the financial sector.

AI Stocks Recovery: Three AI-related semi-IPOs rebounded after previous losses, with MINIMAX-WP, KNOWLEDGE ATLAS, and HAIZHI TECH GP all posting gains and increased trading volumes.

JPMorgan's Upgrade on Chinese Stocks: JPMorgan upgraded its rating of Chinese stocks to Overweight, citing the end of a four-year downward cycle and a favorable entry point for investors, with year-end targets for the MSCI China Index and CSI 300 Index set at 100 and 5,200, respectively.

Shift in Investment Strategy: The firm anticipates a shift in investor focus from short-term trading to long-term appreciation in Chinese stocks, particularly in sectors benefiting from AI, commodities, and consumer staples.

Highlighted Stocks: JPMorgan's investment strategy includes several Chinese stocks rated as Overweight, such as Tencent, Alibaba, and Moutai, with varying short-selling ratios indicating market sentiment.

Market Outlook: The report reflects a more optimistic outlook for leading internet platforms and sectors like robotics and biotechnology, suggesting potential for outperformance in the Chinese market.

Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.

Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.

Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.

Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.